Fiche publication
Date publication
août 2021
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe
,
Dr VIENOT Angélique
,
Dr KIM Stephano
,
Dr BOUSTANI Jihane
Tous les auteurs :
Spehner L, Boustani J, Cabel L, Doyen J, Vienot A, Borg C, Kim S
Lien Pubmed
Résumé
Squamous cell carcinoma of the anus is an orphan disease, and after more than three decades of no substantial advances in disease knowledge and treatment, it is finally gaining momentum with the arrival of a taxane-based chemotherapy and immunotherapy. Currently, about 20 combination clinical trials with an anti-PD1/L1 are ongoing in localized and advanced stages, in association with radiotherapy, chemotherapy, tumor vaccines, anti-CTLA4, anti-EGFR, or antiangiogenic molecules. Moreover, a new biomarker with high sensitivity and specificity such as HPV circulating tumor DNA (HPV ctDNA) by liquid biopsy, is improving not only the prognostic measurement but also the treatment strategy guidance for this disease. Finally, better understanding of potential targets is reshaping the present and future clinical research in this unique, HPV genotype-16-related disease in the great majority of patients.
Mots clés
anal carcinoma, biomarkers, chemotherapy, immunotherapy, research, trials
Référence
Cancers (Basel). 2021 Aug 2;13(15):
